Intestinal Transplantation and Donor‐Specific Antibodies: Another Brick in the Wall
Florence Lacaille – 28 October 2018
Hepatology Highlights
Norihiro Imai, Tibor I. Krisko, Zaid H. Tafesh, Catherine Lucero, Michele Alves‐Bezerra, Hayley T. Nicholls, Sandra Steensels, Baran A. Ersoy, Russell Rosenblatt, Robert E. Schwartz, Vikas Gupta, Zurabi Lominadze, Brett E. Fortune – 27 October 2018
Cover Image
27 October 2018
Masthead
27 October 2018
Notices
27 October 2018
Table of contents
27 October 2018
Instructions to Authors
27 October 2018
Hepatology Highlights
Norihiro Imai, Tibor I. Krisko, Zaid H. Tafesh, Catherine Lucero, Michele Alves‐Bezerra, Hayley T. Nicholls, Sandra Steensels, Baran A. Ersoy, Russell Rosenblatt, Robert E. Schwartz, Vikas Gupta, Zurabi Lominadze, Brett E. Fortune – 27 October 2018
PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization
Henrik Mueller, Anaïs Lopez, Philipp Tropberger, Steffen Wildum, Josephine Schmaler, Lykke Pedersen, Xingchun Han, Yongguang Wang, Søren Ottosen, Song Yang, John A.T. Young, Hassan Javanbakht – 26 October 2018 – RG7834 is a potent, orally bioavailable small‐molecule inhibitor of hepatitis B virus (HBV) gene expression that belongs to the dihydroquinolizinone (DHQ) chemical class and uniquely blocks production of both viral DNA and antigens.
Domestic Transplant Tourism: More Than Just Model for End‐Stage Liver Disease Score Variation
Kristopher P. Croome – 26 October 2018